[
Benezeder, T., Wolf, P. (2019). Resolution of plaque-type psoriasis: What is left behind (and reinitiates the disease). Springer Semin. Immunopathol, 32 (6), 1–12.10.1007/s00281-019-00766-z688141431673756
]Search in Google Scholar
[
Boehncke, W. H., Boehncke, S. (2014). More than skin-deep: The many dimensions of the psoriatic disease. Swiss Med. Wkly., 144 (171), 68–75.10.4414/smw.2014.1396824764145
]Search in Google Scholar
[
Boniface, K., Jacquemin, C., Darrigade, A. S., Dessarthe, B., Martins C., Boukhedouni, N. (2018). Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3. J. Invest. Dermatol., 138 (2), 355–364.10.1016/j.jid.2017.08.03828927891
]Search in Google Scholar
[
Cather, J. C., Crowley, J. J. (2014). Use of biologic agents in combination with other therapies for the treatment of psoriasis. Amer. J. Clin. Dermatol., 15 (6), 467–478.10.1007/s40257-014-0097-1423982525373522
]Search in Google Scholar
[
Chiricozzi, A., Romanelli,. P., Volpe, E., Borsellino, G., Romanelli, M. (2018). Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci., 19 (1), 179–18510.3390/ijms19010179579612829316717
]Search in Google Scholar
[
Christophers, E. (2001) Psoriasis — epidemiology and clinical spectrum. Clin. Exp. Dermatol., 26 (4), 314–320.10.1046/j.1365-2230.2001.00832.x11422182
]Search in Google Scholar
[
Christophers, E., van de Kerkhof, P. C. (2019). Severity, heterogeneity and systemic inflammation in psoriasis. J. Eur. Acad. Dermatol. Venereol., 33 (4), 643–647.10.1111/jdv.1533930924245
]Search in Google Scholar
[
Cosentyx 150 mg powder for solution for injection. SmPC. https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf (accessed 15 March 2020).
]Search in Google Scholar
[
Danese, S., Vermeire, S., D’Haens, G., Panés J., Dignass, A., Magro F. (2020). DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial. J. Crohns Colitis, 14 (1), 49–52.10.1093/ecco-jcc/jjz203.052
]Search in Google Scholar
[
Dubertret, L., Mrowietz, U., Rank., A, Van De Kerkhof, P. C., Chimenti, S., Lotti, T. (2006). EUROPSO patient survey. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Brit. J. Dermatol., 155 (4), 729–736.
]Search in Google Scholar
[
Eder, L., Haddad, A., Rosen C. F., Lee K. A., Chandran V., Cook, R. (2016). The incidence and risk factors for psoriatic arthritis in patients with psoriasis: A prospective cohort study. Arthritis Rheum., 68 (4), 915–923.10.1002/art.3949426555117
]Search in Google Scholar
[
Enbrel 25 mg solution for injection in pre-filled syringe Enbrel 50 mg solution for injection in pre-filled syringe. SmPC. https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf on 10/03/2020 (accessed 01.03.2020).
]Search in Google Scholar
[
From evolution to revolution: IL-23 in the treatment of psoriasis patients. EMJ Dermatol., 6, 71–78. https://www.emjreviews.com/dermatology/symposium/from-evolution-to-revolution-il-23-in-the-treatment-of-psoriasis-patients (accessed 01.03.2020).
]Search in Google Scholar
[
Gaies, E., Jebabli, N., Trabelsi, S., Salouage, I., Charfi, R., Lakhal, M. (2012). Methotrexate side effects: Review article. J. Drug Metab. Toxicol., 3 (4), 1–5.10.4172/2157-7609.1000125
]Search in Google Scholar
[
Gisondi, P., Del Giglio, M., Girolomoni, G. (2017). Treatment approaches to moderate to severe psoriasis. Int. J. Mol., 18 (11), 2427–2429.10.3390/ijms18112427
]Search in Google Scholar
[
Global Psoriasis Atlas. https://globalpsoriasisatlas.org/statistics (accessed 20.04.2020).
]Search in Google Scholar
[
Gooderham, M. J., Papp, K. A., Lynd, C.W. (2018). Shifting the focus–the primary role of IL-23 in psoriasis and other inflammatory disorders. J. Eur. Acad. Dermatol. Venereol., 32 (7), 1111–1119.10.1111/jdv.14868
]Search in Google Scholar
[
Griffiths, C. E., Barker, J. N. (2007). Pathogenesis and clinical features of psoriasis. The Lancet, 370, 263–271.10.1016/S0140-6736(07)61128-3
]Search in Google Scholar
[
Hao, J. Q. (2014). Targeting interleukin-22 in psoriasis. Inflammation, 37 (1), 94–99.10.1007/s10753-013-9715-y23978911
]Search in Google Scholar
[
Hartmane, I., Mikažāns, I., Ivdra,. I, Dērveniece, A., Ančupāne, I. (2016). Experience of phototherapy in dermatological praxis in complex therapy of psoriasis patients. Proc. Latv. Acad. Sci. Section B, 70 (1), 7–12.10.1515/prolas-2016-0002
]Search in Google Scholar
[
Humira 40 mg solution for injection in pre-filled syringe Humira 40 mg solution for injection in pre-filled pen. SmPC. Last revised 08/09/2008. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf (accessed 15.03.2020).
]Search in Google Scholar
[
Ilumetri 100 mg solution for injection in pre-filled syringe. SmPC. Last revised 17/09/2018. https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf on 10/03/2020 (accessed 15.03.2020).
]Search in Google Scholar
[
Jain, S., Kaur, I. R., Das, S., Bhattacharya, S. N. Singh, A. (2009) T helper 1 to T helper 2 shift in cytokine expression: An autoregulatory process in superantigen-associated psoriasis progression? J. Med. Microbiol., 58 (2), 180–184.10.1099/jmm.0.003939-019141734
]Search in Google Scholar
[
Kerdel, F., Zaiac, M. (2015). An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol. Ther., 28 (6), 390–403.10.1111/dth.12267504207326258910
]Search in Google Scholar
[
Kyntheum 210 mg solution for injection in pre-filled syringe. SmPC. Last revised 17/07/2017. https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf (accessed 15.03. 2020).
]Search in Google Scholar
[
Li, K., Joshua, F. R., Marano, C., Zhang, H., Yang, F., Feagan, B. G. (2019). Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in Ulcerative Colitis. Z. Gastroenterol., 57 (5), 169–187.10.1055/s-0039-1691867
]Search in Google Scholar
[
Mahil, S. K., Capon, F., Barker J. N. (2016). Update on psoriasis immuno-pathogenesis and targeted immunotherapy. Springer Semin. Immunopathol., 38 (1), 11–27.
]Search in Google Scholar
[
Malik, B. T., Byrne, K. T., Vella, J. L., Zhang, P., Shabaneh, T. B., Steinberg, S. M. (2017). Resident memory T cells in skin mediate durable immunity to melanoma. Sci. Immunol., 2 (10), 35–47.10.1126/sciimmunol.aam6346552533528738020
]Search in Google Scholar
[
Marti, D. A.,Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G. (2013). The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. J. Invest Dermatol., 133 (1), 17–26.10.1038/jid.2012.194356899722673731
]Search in Google Scholar
[
Matos, T. R., O’Malley, J. T., Lowry, E. L., Hamm, D., Kirsch I. R. (2017). Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αā T cell clones. J. Clin. Invest., 127 (11), 4031–4041.10.1172/JCI93396566336628945199
]Search in Google Scholar
[
Mattozzi, C., Salvi M., D’epiro, S., Giancristoforo, S., Macaluso, L., Luci, C. (2013). Importance of regulatory T cells in the pathogenesis of psoriasis. Dermatology, 227 (2), 134–145.10.1159/00035339824051528
]Search in Google Scholar
[
Medicines to be reimbursed. Nacionālais Veselības Dienests [National Health Service]. http://www.vmnvd.gov.lv/en/cross-border-healthcare-contact-point/health-care-in-latvia/medicines-to-be-reimbursed on 06/04/2020 (accessed 15.04. 2020).
]Search in Google Scholar
[
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B. (2011). Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J. Amer. Acad. Dermatol., 65 (1), 137–174.10.1016/j.jaad.2010.11.05521306785
]Search in Google Scholar
[
Ministry of Health of the Republic of Lithuania. http://sam.lrv.lt/en/ (accessed 15.04.2020).
]Search in Google Scholar
[
Möller, A. H, Erntoft, S., Vinding, G. R., Jemec G. B. (2015). A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat. Outcome Meas., 6, 167–177.
]Search in Google Scholar
[
Monteleone, G., Pallone F., MacDonald, T. T., Chimenti, S., Costanz, A. (2011). Psoriasis: From pathogenesis to novel therapeutic approaches. Clin. Sci., 120 (1), 8–12.10.1042/CS2010016320846119
]Search in Google Scholar
[
Mrowietz, U., De Jong, E. M., Kragballe, K., Langley, R., Nast, A., Puig, L. (2014). A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol., 28 (4), 438–453.10.1111/jdv.1211823437792
]Search in Google Scholar
[
Mrowietz, U., Kragballe, K., Reich, K., Spul, P., Griffiths. C. E., Nast, A. (2011). Definition of treatment goals for moderate to severe psoriasis:A European consensus. Arch. Dermatol. Res., 303 (1), 1–10.
]Search in Google Scholar
[
Nast, A., Boehncke, W. H., Mrowietz, U., Ockenfels, H. M., Philipp, S., Reich, K. (2012). S3–Guidelines on the treatment of psoriasis vulgaris (English version). Update. J. Dtsch. Dermatol. Ges., 10, 1–95.10.1111/j.1610-0387.2012.07919.x22386073
]Search in Google Scholar
[
Order for the approval of the procedure for the treatment of psoriasis with medicinal products the purchase of which is covered by the compulsory health insurance fund’s budget. Ministry of Health of Republic of Lithuania. https://www.e-tar.lt/portal/en/legalAct/c51f3b408d8311e7a3c4a5eb10f04386/nHZdKhSspS on 06/04/2020 (accessed 15.04.2020) (in Lithuanian).
]Search in Google Scholar
[
Owczarczyk-Saczonek, A., Czerwińska, J., Placek, W. (2018). The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. Acta Dermatovenerol. Alp. Pannonica Adriat., 27 (1), 17–23.10.15570/actaapa.2018.4
]Search in Google Scholar
[
Parisi, R., Symmons, D. P, Griffiths, C. E, Ashcrof, D. M.(2013). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol.., 133 (2), 377–385.10.1038/jid.2012.33923014338
]Search in Google Scholar
[
Qu, N., Xu, M., Mizoguchi, I., Furusawa, J. I., Kaneko, K., Watanabe, K. (2013). Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin. Dev. Immunol., 34 (16), 231–235.10.1155/2013/968549372850723956763
]Search in Google Scholar
[
Rahman, P., Elder, J. T. (2005). Genetic epidemiology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 64 (2), 37–49.10.1136/ard.2004.030775176686815708933
]Search in Google Scholar
[
Rahman, P., Siannis, F., Butt, C., Farewell, V., Peddle, L., Pellett, F (2006). TNFα polymorphisms and risk of psoriatic arthritis. Ann. Rheum. Dis., 65 (7), 919–923.
]Search in Google Scholar
[
Reich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S (2019). Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial. The Lancet, 394 (1 0201), 831–839.10.1016/S0140-6736(19)31773-8
]Search in Google Scholar
[
Reich, K. (2012). The concept of psoriasis as a systemic inflammation: Implications for disease management. J. Eur. Acad. Dermatol. Venereol., 26, 3–11.10.1111/j.1468-3083.2011.04410.x22356630
]Search in Google Scholar
[
Reich, K., Burden, A. D., Eaton, J. N., Hawkins, N. S. (2012). Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials. Brit. J. Dermatol., 166 (1), 179–188.10.1111/j.1365-2133.2011.10583.x21910698
]Search in Google Scholar
[
Reich, K., Nestle, F. O., Papp, K., Ortonne, J. P., Evans, R, Guzzo, C., Li, S., Dooley, L. T., Griffiths, C. E., (2005). EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. The Lancet, 366 (9494), 1367–1374.
]Search in Google Scholar
[
Reimbursemen drug list. Nacionālais Veselības Dienests [National Health Service]. http://www.vmnvd.gov.lv/lv/kompensejamie-medikamenti/kompensejamo-zalu-saraksts from 06/04/2020 (accessed 15.04. 2020).10.36268/JTER/15202
]Search in Google Scholar
[
Remsima 100 mg powder for concentrate for solution for infusion. SmPC. Last revised 21/06/2018. https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf (accessed 15.04. 2020).
]Search in Google Scholar
[
Rendon, A, Schäkel, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20 (6), 1475.10.3390/ijms20061475647162830909615
]Search in Google Scholar
[
Signorovitch, J. E., Betts, K.A., Yan, Y. S., LeReun, C., Sundaram, M., Wu, E. Q., Mulani, P. (2015). Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response. Brit. J. Dermatol., 172 (2), 504–512.10.1111/bjd.1343725288183
]Search in Google Scholar
[
Skyrizi 75 mg solution for injection in pre-filled syringe. SmPC. Last revised 26/04/2019. https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf (accessed 15.04.2020).
]Search in Google Scholar
[
STELARA 45 mg solution for injection STELARA 90 mg solution for injection STELARA 45 mg solution for injection in pre-filled syringe STELARA 90 mg solution for injection in pre-filled syringe. SmPC. Last revised 19/09/2013. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf (accessed 15.04.2020).
]Search in Google Scholar
[
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie A., Van Voorhees A. S. (2017). Psoriasis and comorbid diseases: Epidemiology. J. Amer. Acad. Dermatol.. 76 (3), 377–390.10.1016/j.jaad.2016.07.064573165028212759
]Search in Google Scholar
[
Taltz 80 mg solution for injection in pre-filled syringe. SmPC. Last revised 25/04/2016. https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf (accessed 15.04. 2020).
]Search in Google Scholar
[
Tervishoiuteenuste loetelu. https://www.haigekassa.ee/partnerile/raviasutusele/tervishoiuteenuste-loetelu on 06/04/2020 (accessed 15.04.2020).10.1055/s-0040-1721630
]Search in Google Scholar
[
Tremfya 100 mg solution for injection in pre-filled syringe. Tremfya 100 mg solution for injection in pre-filled pen. SmPC. Last revised 10/11/2017. https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf (accessed 15.04. 2020).
]Search in Google Scholar
[
Use of public budget resources to pay national reimburses [Valsts budžeta līdzekļu izlietojums valsts kompensējamo zāļu apmaksā]. Nacionālais Veselības Dienests [National Health Service]. http://vmnvd.gov.lv/lv/ligumpartneriem/operativa-budzeta-informacija/valsts-budzeta-lidzeklu-izlietojums-valsts-kompensejamo-zalu-apmaksa on 07/04/2020 (accessed 15.04.2020).
]Search in Google Scholar
[
Vide, J., Magina S, (2017). Moderate to severe psoriasis treatment challenges through the era of biological drugs. An. Bras. Dermatol., 92 (5), 668–674.10.1590/abd1806-4841.20175603567470029166504
]Search in Google Scholar
[
Wada, Y., Cardinale, I., Khatcherian, A., Chu, J., Kantor, A. B., Gottlieb, A.B. (2012). Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PloS One, 7 (4), 1371–1380.10.1371/journal.pone.0035069332087322493730
]Search in Google Scholar
[
Watanabe, R. (2019). Protective and pathogenic roles of resident memory T cells in human skin disorders. J. Dermatol. Sci., 31 (5), 151–157.10.1016/j.jdermsci.2019.06.00131272851
]Search in Google Scholar
[
Yeung, H., Takeshita, J., Mehta, N. N., Kimmel, S. E., Ogdie, A., Margolis, D. J., Shin, D. B., Attor, R., Troxel, A. B., Gelfand, J. M. (2013). Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatol., 149 (10), 1173–1179.10.1001/jamadermatol.2013.5015380048723925466
]Search in Google Scholar
